Santaris Pharma and miRagen Therapeutics have extended their worldwide strategic alliance to discover and develop LNA-drugs targeting disease causing microRNAs.
Under the extended agreement miRagen gains an extensive non-exclusive license in the miRNA therapeutics field for therapeutics research and global rights to develop and commercialise LNA drugs against six additional microRNA targets.
With the addition of these targets, which concern human disease areas of high unmet need, the total number of targets under the agreement reaches ten.
Santaris Pharma business development CSO and VP Henrik Ørum said the collaboration with miRagen is an important part of the company’s corporate strategy in the microRNA therapeutics field.
"MicroRNA therapy is an exciting new branch of human medicine where the LNA drug platform has already provided proof-of-concept in Phase II clinical studies in HCV patient using Santaris´miRNA-122 inhibitor, Miravirsen," Ørum said.
As a part of the deal, Santaris will earn a combination of cash and equity for the licenses, in addition to clinical milestones and royalties on products resulting from the alliance.
Financial terms of the transaction were not revealed.
miRagen president and CEO William Marshall said the partnership with Santaris has been very productive.
"Our goal is to identify important disease causing microRNAs and to deploy the world’s best technologies to create therapeutic development candidates against diseases with high unmet medical need," Marshall said.